Heron Therapeutics (HRTX) vs Zhengye Biotechnology (ZYBT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Zhengye Biotechnology (ZYBT) has outperformed Heron Therapeutics (HRTX) over the past year, losing 47.4% versus a loss of 72.0%. Heron Therapeutics is the larger company by market cap ($68.5 million vs $66.3 million), about 1.0 times the size. Heron Therapeutics converts more of its revenue into profit, with a net margin of -13.0% versus -60.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HRTX | ZYBT |
|---|---|---|
| Share price | $0.361 | $1.40 |
| Market cap | $68.54M | $66.35M |
| 1-day change | -4.12% | -6.67% |
| YTD return | -72.23% | +21.74% |
| 1-year return | -72.02% | -47.37% |
| 5-year return | -96.57% | — |
| EPS (TTM) | $-0.18 | $-0.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $154.90M | $16.64M |
| Revenue growth (YoY) | +7.36% | -34.83% |
| Net income (latest FY) | $-20.20M | $-9.98M |
| Gross margin | 73.31% | 20.51% |
| Operating margin | -1.64% | -60.60% |
| Net margin | -13.04% | -59.99% |
| 52-week high | $1.58 | $8.01 |
| 52-week low | $0.26 | $0.616 |
| Distance from 52-week high | -77.15% | -82.52% |
| Analyst consensus | none | — |
| Avg. price target upside | +1839.06% | — |
| Average volume | 2.43M | 5.64M |
| Shares outstanding | 189.85M | 47.39M |
| Employees | 128 | 269 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ZYBT has outperformed HRTX by 24.6 percentage points over the past year.
- Heron Therapeutics is more profitable, keeping -13.0 cents of every revenue dollar as net income versus -60.0 cents for Zhengye Biotechnology.
- Heron Therapeutics grew revenue faster in its latest fiscal year (+7.36% vs -34.83%).
About Heron Therapeutics
HRTX stock →Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees
About Zhengye Biotechnology
ZYBT stock →Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in the People's Republic of China. The company offers vaccines for swine, cattle, goats, sheep, poultry, and dogs, as well as monovalent vaccine, polyvalent vaccine, combined vaccine, and combined and polyvalent vaccine.
Health Care · Biotechnology: Pharmaceutical Preparations · 269 employees
HRTX vs ZYBT FAQ
Which is bigger, Heron Therapeutics or Zhengye Biotechnology?
Heron Therapeutics (HRTX) is larger, with a market capitalization of $68.54M compared with $66.35M for Zhengye Biotechnology (ZYBT).
Which stock has performed better over the past year, HRTX or ZYBT?
ZYBT returned -47.37% over the past 12 months, compared with -72.02% for HRTX (price return, excluding dividends). Past performance does not predict future results.
Are Heron Therapeutics and Zhengye Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.